Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous human-derived anti-CD19 CAR-T cells
- Development stage
- Unknown
- Lead developer
- Shanghai YaKe Biotechnology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous human-derived anti-CD19 CAR-T cells (specifically developed under the code YK-hCD19BB-002) represent an investigational chimeric antigen receptor (CAR) T-cell therapy designed to target CD19-positive B-cell malignancies, including relapsed or refractory acute lymphoblastic leukemia (r/r B-ALL). Unlike conventional CAR-T therapies that utilize murine-derived single-chain variable fragments (scFvs) which can trigger immunogenic clearance and limit persistence, this therapy employs a fully human or human-derived scFv. The CAR construct typically incorporates a 4-1BB costimulatory domain and a CD3ζ signaling domain. By utilizing patient-derived T cells engineered to express this humanized CAR, the therapy aims to minimize immunogenicity, enhance in vivo persistence, and improve clinical outcomes in patients who have relapsed after or are resistant to prior murine-derived CD19 CAR-T therapies.
- Other names
- hCART19hCART-19hCART 19hCD19 CAR-T cellshCD-19 CAR-T cellshCD 19 CAR-T cellshumanized CD19 CAR-T cells
02
Targets
Beyond the preview
Go deeper on autologous human-derived anti-CD19 CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous human-derived anti-CD19 CAR-T cells.